1 BTC
=
- USD
Cytokinetics Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Cytokinetics Inc.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Market Statistics
Trading Metrics
How to Buy CYTK
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy CYTK
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesCytokinetics announced that its management team will participate in two major investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. The company will host fireside chats at both events, with live webcasts available on its investor relations website.
Cytokinetics granted stock options to purchase 20,807 shares and 13,793 RSUs to 8 newly hired employees on May 15, 2026 as material inducements to employment. The stock options have an exercise price of $75.85 per share and vest over 4 years, while RSUs vest over 3 years. The company is a specialty cardiovascular biopharmaceutical firm with its approved drug MYQORZO® for obstructive hypertrophic cardiomyopathy and several investigational candidates in development.
Cytokinetics announced that its management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company will discuss its cardiovascular biopharmaceutical pipeline, including MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy and ongoing development of omecamtiv mecarbil and ulacamten for heart failure treatments.
Cytokinetics announced it will report first quarter 2026 results on May 5, 2026, followed by a conference call at 4:30 PM ET. The specialty cardiovascular biopharmaceutical company will discuss financial results and provide business updates on its pipeline including MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy and investigational drugs omecamtiv mecarbil and ulacamten for various heart failure indications.
Sarissa Capital Management established a new $5.79 million position in clinical-stage biotech Biohaven, acquiring 513,184 shares during Q4 2025. Despite the stock falling 70% over the past year due to FDA rejection of troriluzole and disappointing trial results, the fund's investment signals potential turnaround prospects. Biohaven has refocused on late-stage programs including a degrader platform and Phase 2 obesity candidate with data expected in H2 2026, while maintaining a strengthened balance sheet with $500.9 million in cash.
